Next Article in Journal
New Gastropod Vectors and Tetrodotoxin Potential Expansion in Temperate Waters of the Atlantic Ocean
Previous Article in Journal
Temporal Trends in the Secondary Metabolite Production of the Sponge Aplysina aerophoba
Article Menu

Export Article

Open AccessArticle
Mar. Drugs 2012, 10(4), 694-711; doi:10.3390/md10040694

A Marine Anthraquinone SZ-685C Overrides Adriamycin-Resistance in Breast Cancer Cells through Suppressing Akt Signaling

1,2,3,†
,
1,2,3,†
,
1,2,3,†
,
1,2,4
,
1,2,3
,
1,2,3
,
5,6
,
1,2,3
,
1,2
,
1,2
,
1,2
,
1,2
,
2,7
,
2,7
,
2,7
,
1,2
,
2,7
and
1,2,3,*
1
Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou 510080, China
2
Guangdong Province Key Laboratory of Functional Molecules in Oceanic Microorganism (Sun Yat-sen University), Bureau of Education, Guangzhou 510080, China
3
Department of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China
4
Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China
5
Department of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road II, Guangzhou 510080, China
6
Department of Cardiology, The First People’s Hospital of Zigong, 42 Shangyihao Road I, Zigong 643000, China
7
School of Chemistry and Chemical Engineering, Sun Yat-sen University, Guangzhou 510275, China
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 14 February 2012 / Revised: 13 March 2012 / Accepted: 14 March 2012 / Published: 23 March 2012
View Full-Text   |   Download PDF [4400 KB, uploaded 24 February 2015]   |  

Abstract

Breast cancer remains a major health problem worldwide. While chemotherapy represents an important therapeutic modality against breast cancer, limitations in the clinical use of chemotherapy remain formidable because of chemoresistance. The HER2/PI-3K/Akt pathway has been demonstrated to play a causal role in conferring a broad chemoresistance in breast cancer cells and thus justified to be a target for enhancing the effects of anti-breast cancer chemotherapies, such as adriamycin (ADR). Agents that can either enhance the effects of chemotherapeutics or overcome chemoresistance are urgently needed for the treatment of breast cancer. In this context, SZ-685C, an agent that has been previously shown, as such, to suppress Akt signaling, is expected to increase the efficacy of chemotherapy. Our current study investigated whether SZ-685C can override chemoresistance through inhibiting Akt signaling in human breast cancer cells. ADR-resistant cells derived from human breast cancer cell lines MCF-7, MCF-7/ADR and MCF-7/Akt, were used as models to test the effects of SZ-685C. We found that SZ-685C suppressed the Akt pathway and induced apoptosis in MCF-7/ADR and MCF-7/Akt cells that are resistant to ADR treatment, leading to antitumor effects both in vitro and in vivo. Our data suggest that use of SZ-685C might represent a potentially promising approach to the treatment of ADR-resistant breast cancer. View Full-Text
Keywords: SZ-685C; breast cancer; chemoresistance; Akt SZ-685C; breast cancer; chemoresistance; Akt
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Zhu, X.; He, Z.; Wu, J.; Yuan, J.; Wen, W.; Hu, Y.; Jiang, Y.; Lin, C.; Zhang, Q.; Lin, M.; Zhang, H.; Yang, W.; Chen, H.; Zhong, L.; She, Z.; Chen, S.; Lin, Y.; Li, M. A Marine Anthraquinone SZ-685C Overrides Adriamycin-Resistance in Breast Cancer Cells through Suppressing Akt Signaling. Mar. Drugs 2012, 10, 694-711.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top